AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

48.55USD
1:30am IST
Price Change (% chg)

$0.43 (+0.89%)
Prev Close
$48.12
Open
$47.92
Day's High
$48.78
Day's Low
$47.72
Volume
1,696,805
Avg. Vol
1,759,858
52-wk High
$54.72
52-wk Low
$40.11

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a research-based pharmaceuticals company. The Company discovers, develops, and commercializes advanced therapies. AbbVie's portfolio of products include a line of adult and pediatric pharmaceuticals, which includes HUMIRA, metabolics/hormones products, virology products, endocrinology products, dyslipidem... (more)

Overall

Beta: --
Market Cap (Mil.): $76,801.94
Shares Outstanding (Mil.): 1,596.05
Dividend: 0.42
Yield (%): 3.49

Financials

  ABBV.N Industry Sector
P/E (TTM): 18.74 32.99 33.14
EPS (TTM): 2.57 -- --
ROI: 19.40 19.69 18.95
ROE: 105.11 20.38 19.71
Search Stocks

AbbVie drops legal action in EU drug secrecy case

LONDON - AbbVie, one of the two U.S. companies trying to stop Europe's drugs regulator from releasing previously secret clinical trials data, said on Thursday it had withdrawn lawsuits against the watchdog.

04 Apr 2014

UPDATE 1-AbbVie drops legal action in EU drug secrecy case

* Decision follows EMA acceptance of redactions to documents

04 Apr 2014

AbbVie drops drug secrecy case against EU agency

LONDON, April 3 - AbbVie, one of the two U.S. firms bringing an injunction against Europe's drugs regulator over the issue of trial data secrecy, said on Thursday it had withdrawn its lawsuit.

03 Apr 2014

AbbVie to build manufacturing plant in Singapore

Feb 5 - U.S. drugmaker AbbVie Inc on Wednesday said it will spend $320 million to set up a manufacturing facility in Singapore to produce new drugs for cancer and immunology now in development.

06 Feb 2014

AbbVie sees 2014 approval of hepatitis drugs, shares rise

- AbbVie Inc issued a cautious 2014 profit forecast, but said it expects U.S. approval this year for its potentially lucrative new all-oral treatment for hepatitis C, sending its shares up 3.4 percent.

31 Jan 2014

AbbVie 4th-quarter earnings slide, hit by generics competition

Jan 31 - AbbVie Inc on Friday reported lower fourth-quarter earnings, hurt by generic competition for its medicines, but results matched Wall Street expectations.

31 Jan 2014

Stellar hepatitis C data puts Gilead farther ahead of pack

- Gilead Sciences Inc released impressive late-stage data Wednesday for its once-daily combination pill to treat hepatitis C, advancing its lead in the race to develop new, all-oral treatments for the liver disease, and pushed up its timeline for seeking U.S. approval.

19 Dec 2013

UPDATE 3-Stellar hepatitis C data puts Gilead farther ahead of pack

Dec 18 - Gilead Sciences Inc released impressive late-stage data Wednesday for its once-daily combination pill to treat hepatitis C, advancing its lead in the race to develop new, all-oral treatments for the liver disease, and pushed up its timeline for seeking U.S. approval.

19 Dec 2013

AbbVie drug shows promise against difficult type of breast cancer

- Women with an especially deadly type of breast cancer who received a treatment regimen containing an experimental AbbVie Inc drug prior to surgery are likely to have a significantly better response than those who get a standard chemotherapy regimen, according to data from a clinical trial.

13 Dec 2013

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $98.96 +0.21
Pfizer Inc. (PFE.N) $30.25 +0.16
Novartis AG (NOVN.VX) CHF74.70 +0.35
Merck & Co., Inc. (MRK.N) $56.47 +0.21
Roche Holding Ltd. (ROG.VX) CHF254.90 +0.70
Abbott Laboratories (ABT.N) $38.93 +0.55
Eli Lilly and Co (LLY.N) $60.43 +0.47

Earnings vs. Estimates

Search Stocks